Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Sees Significant Drop in Short Interest

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) saw a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 117,500 shares, a decrease of 74.3% from the December 31st total of 457,500 shares. Based on an average daily volume of 3,580,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.8% of the company’s stock are short sold.

Analyst Ratings Changes

Separately, Maxim Group reissued a “hold” rating on shares of Virpax Pharmaceuticals in a research report on Wednesday, October 9th.

Hedge Funds Weigh In On Virpax Pharmaceuticals

A hedge fund recently bought a new stake in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC bought a new stake in shares of Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned about 1.17% of Virpax Pharmaceuticals as of its most recent SEC filing. 32.23% of the stock is owned by institutional investors.

Virpax Pharmaceuticals Trading Down 3.5 %

Shares of NASDAQ VRPX opened at $0.31 on Friday. The company has a 50-day moving average price of $0.36 and a 200-day moving average price of $0.68. Virpax Pharmaceuticals has a 1 year low of $0.23 and a 1 year high of $5.48.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.